About Phoenix Tissue Repair & BridgeBio Pharma
Phoenix Tissue Repair, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB) a rare genetic disease affecting the skin and other organs. Our dedicated team of industry veterans is working to develop BBP-589, an investigational protein replacement therapy that uses a recombinant collagen type VII (rC7) to treat RDEB. BBP-589 represents the only potentially disease-modifying treatment in development that may solve the systemic manifestations of RDEB and the more visible skin-related aspects of this devastating disease.
BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs.
Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, Boston, New York, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zug, Switzerland, and are expanding across Europe.
To learn more about our story and company culture, visit us at phoenixtissuerepair.com |
Any office location
Who You Are:
Phoenix Tissue Repair is hiring a Vice President, Regulatory Affairs, to lead, develop and execute global regulatory strategies aimed at the most efficient regulatory pathway for the Company’s drug development program. This involves collaboration with cross-functional project teams in planning development strategies and leading global regulatory submissions for assigned projects. The incumbent may also be responsible for supporting Company growth and infrastructure activities and execute on strategies developed.
Education, Experience & Skills Requirements:
What We Offer:
We will not accept unsolicited resumes from agencies. Please do not send agency resumes to our website or BridgeBio and affiliating employees.